Resumo

SANCHEZ-LOPEZ, P; PRATS-OLIVAN, P; APARICIO-HERNANDEZ, R  e  SILVA-CUEVAS, MA. Positive assessment of drugs: November, December 2020, and January, February 2021. Sanid. Mil. [online]. 2021, vol.77, n.3, pp.143-149.  Epub 17-Jan-2022. ISSN 1887-8571.  https://dx.doi.org/10.4321/s1887-85712021000300005.

The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in November, December of 2020 and January, February of 2021 , and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.

Palavras-chave : Elzonris®; Phesgo®; Roclanda®; Xofluza®; Onbevzi®; Alymsys/Oyavas®; Abevmy/Lextemy®; Enhertu®; Tukysa®; Retsevmo®; Lumoxiti®; Inrebic®; Heplisav B®; Sibnayal®; Rukobia®; Ogluo®; Kixelle®; Yuflyma®; Vaccine (ChAdOx1-S [recombinant]); COVID-19 Vaccine AstraZeneca®; Vaxzevria®; Pemazyre®; Nexpovio®; Ontozry®; Kesimpta®; Byfavo®; Vazkepa®; Sogroya®; Seffalair/Spiromax®/BroPair Spiromax®; Evrysdi®; Jemperli®; Orladeyo®.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )